Faculty of Medicine Biochemistry, Microbiology and Immunology

• Home
  • News & Announcements
  • Awards
  • Department Programs
• Directory
  • Faculty Members
  • Postdoctorate Fellows
  • Support Staff
• Applications & Positions
• Centers and Services
• Research
• International Collaboration
  • International Visits
  • Funding Opportunities
• Seminars
• Undergraduate Program in Biochemistry
• Graduate Programs in Biochemistry or Microbiology and Immunology
• Students & Funding Opportunities
• Links
• BMI Grad Student Association
• BMI Recent Publications

Sean (Xuguang) Li

Adjunct Professor 

Department of Biochemistry, Microbiology, and Immunology

Degrees:

M.D., Medical College of Suzhou University
Ph.D., McGill University
Post-Doctoral Fellow, Dana Farber Cancer Institute, Harvard Medical School

Contact info:

Office: Center for Biologics Research/Vaccine Evaluation,
Biologics and Genetic Therapies Directorate, HPFB, Health Canada
Address Locator: 2201E, 1st Floor, Frederick G. Banting Building
Tunney's Pasture
Ottawa, ON K1A 0K9

Phone: (613) 954-2383 (Office); 
Fax: (613) 941-8933
E-mail: sean.li@hc-sc.gc.ca

Research Interests:

Dr. Sean (Xuguang) Li received his medical training in Suzhou, China, followed by a graduate study training period in medical research in Beijing. In 1996 he obtained his PhD from McGill University under the supervision of Prof Mark Wainberg. From 1996 to 2000, he was a Research Fellow at the Dana Farber Cancer Institute/Harvard Medical School with Dr. Wayne Marasco. Currently, Dr. Li is a Senior Scientist at Health Canada, while serving as an Adjunct Professor at BMI and a member of Faculty of the Graduate and Postdoctoral Studies, University of Ottawa.
The following are highlights of his research activities:

1. Gene Therapy and Biotherapeutics
2. Molecular and Immunological Studies on Viruses of Medical Importance
3. Antiviral and Vaccine Research
4. Antibody Engineering

Selected Publications:

• Hashem AM, B. Jaentschke,  C. Gravel,  M Tocchi, TM Doyle, M Rosu-Myles, R He, X. Li. 2012 Subcutaneous immunization with recombinant adenovirus expressing influenza A nucleoprotein protects mice against lethal viral challenge. Human Vaccine (in press).
• Russell M, C. Li,,  L. Larocque, A. Farnsworth, J. Wang, R He, X. Li.  2011  Rapid and Accurate Determination of the Potency of Varicella Vaccine by Quantitative Polymerase Chain Reaction. Vaccine 2011 Nov 3;29(47):8490-5.
• Hashem AM, TM Doyle, G Van Domselaar, A Farnsworth, C Li, J Wang, R He, X. Li. 2011, Recent Developments in Bioinformatics Analyses of Influenza A Virus Surface Glycoproteins and their Biological Relevance. Current Bioinformatics 6(4): 415 -426.
• Flaman AS, C Gravel, A.M. Hashem,  M Tocchi,  X. Li. 2011 The effect of interferon- on the expression of cytochrome P450 3A4 in human hepatoma cells. Toxicol Appl Pharmacol.  253:130–136.
• Johnston MJ, Frahm G, X. Li, Durocher Y, Hefford MA. 2011. O-linked glycosylation leads to decreased thermal stability of interferon alpha 2b as measured by two orthogonal techniques. Pharmaceutical Research. 28(7):1661-1667.
• Lorbetskie B, J. Wang, C. Gravel, C. Allen, M. Walsh, A.Rinfret, X. Li, and M Girard. 2011. Quantitative Analysis of Hemagglutinin in Influenza Vaccine Preparations by Reversed-Phase HPLC on Non-Porous Silica: Optimization, Qualification, Comparative Evaluation with Western Blot and Single Radial Immunodiffusion Assays and Applicability during the 2009 H1N1 Influenza
  Pandemic. Vaccine 29(18):3377-89.
• Larocque L, A. Bliu, R. Xu, A Diress, J Wang, R. Lin, R. He, M. Girard, X. Li . 2011. Bioactivity determination of native and variant forms of therapeutic interferons. J. Biomed. Biotechnol. 2011;2011:174615
• Farnsworth A., T.D. Cyr, C. Li, J. Wang, and X. Li. 2011. Antigenic stability of H1N1 pandemic vaccines correlates with vaccine strain. Vaccine 29(8):1529-33
• Gravel C, C Li, J Wang, B Jaentschke, G Van Domselaar, R He, X. Li. 2011.  Quantitative Analyses of all Influenza Type A Viral Hemagglutinins and Neuraminidases using Universal Antibodies in simple Slot Blot Assays. J. Vis. Exp. 2011 Apr 4;(50). pii: 2784. doi: 10.3791/2784.
• Hashem A, G. Van Domselaar, C. Li, J. Wang, Y-M She, T.D. Cyr, J. Sui, R. He, W.A. Marasco, X. Li. 2010.Universal Antibodies against the Highly Conserved Influenza Fusion Peptide Cross-Neutralize Several Subtypes of Influenza A Virus. Biochem Biophys Res Comm. 403: 247–251
• Gravel C, C. Li, J. Wang, AM. Hashem, B. Jaentschke, KW Xu, B. Lorbetskie, G. Gingras, Y. Aubin, GV Domselaar, M. Girard, R. He, X. Li  2010 Qualitative and quantitative analyses of virtually all subtypes of influenza A and B viral neuraminidases using antibodies targeting the universally conserved sequences  Vaccine. 28(36):5774-84.
• Farnsworth A, A S. Flaman, S. S. Prassad, C. Gravel, A. Williams, C.L. Yauk,  X. Li 2010 Modulation of the transcriptional response to recombinant IFN-ß following the administration of Acetaminophen. Plos One. 5(6): e11031.
• Li C, B. Jaentschke, Y. Song, J. Wang, T. Cyr, G. Van Domselaar, R. He, X. Li.  2010. A simple slot blot for the detection of virtually all subtypes of the influenza A viral hemagglutinins using universal antibodies targeting the fusion peptide. Nat. Protoc. 5(1):14-19.
• Li C, M. Shao,  X. Cui, Y. Song, J. Li, L. Yuan, H. Fang, Z. Liang, T.D. Cyr, F. Li, X. Li,  J. Wang. 2010. Application of deglycosylation and electrophoresis to the quantification of influenza viral hemagglutinins facilitating the production of 2009 pandemic influenza (H1N1) vaccines at multiple manufacturing sites in China. Biologicals. 38(2):284-9.
• Diress A, Lorbetskie B, Larocque L, X. Li, M. Alteen, R. Isbrucker and M. Girard. 2009. Study of aggregation, denaturation and reduction of interferon alpha-2 products by size-exclusion HPLC with fluorescence detection and biological assays. Journal of Chromatgraphy A 1217(19):3297-3306.
• Chiang S, Burch T, Radzivon A, Dick K, Cutts T, Cao J, Li X, and R. He The interaction between thymidine DNA glycosylase and nuclear receptor Coactivator 3 is important for the transcriptional Activation of Setriod Hormone nuclear receptors. Mol Cell Biochem. 2009. 333 (1-2), pp. 221-232
• Hashem, AM, AS Flaman, A Farnsworth, EG Brown, G. Van Domselaar, R He, X. Li. 2009. Aurintricarboxylic Acid is a Potent Inhibitor of Influenza A and B Virus Neuraminidases. PloS One  5(1):14-19.
• Li, X, T.D Cyr, M. Girard, C Li, J Wang, G Van Domselaar, A Farnsworth, H MacDonald-Piquard, R He. 2009. Advances in quantitative analyses of the hemagglutinin of influenza A viruses and vaccines. In Global view of the fight against influenza Page 209 - 220. P.M. Mitrasinovic (Eds). 2009, ISBN: 978-1-60741-952-5. Nova Science Publishers. Commack, N.Y. USA.p. 209-220.
• Tylor S, A. Andonov, T. Cutts, J. Cao, E. Grudesky, G. Van Domselaar, X.Li, R. He. 2009. The SR-Rich Motif In SARS-CoV Nucleocapsid Protein Is Important For Virus Replication.  Can. J. Microbiol. 55(3):254-60.
• Mark J, X. Li., T.D. Cyr, S. Fournier; B. Jaentschke, M.A. Hefford. 2008. SARS Coronavirus:  Unusual Lability of the Nucleocapsid Protein.  Biochem Biophys Res Comm 377(2):429-33.
• Chun S, C. Li, G. Van Domselaar, J. Wang, A. Farnsworth, X. Cui, H. Rode, T.D. Cyr,  R.He ,  X. Li  2008. Universal antibodies and their applications to the quantitative determination of virtually all subtypes of the influenza A viral hemagglutinins. Vaccine 26(48):6068-76.
• LeBrun, M, H. Huang, and X. Li.  2008. Susceptibility of Cell Substrates to PrPSc Infection and Safety Control Measures Related to Biological and Biotherapeutical Products. Prion. 2 (1):17-22.
• LeBrun, M, H. Huang, R. He, S. Booth, A. Balachandran, X. Li. Comparison of Trichloroacetic Acid with Other Protein-Precipitating Agents in Enriching Abnormal Prion Protein for Western Blot Analysis. Can. J. Microbiol. 2008; 54(6):467-71.
• Flaman AS,  H. Albaghdadi, J. McClintock, T. Cutts, A. Hashem, M. LeBrun, J. Austin, E. Brown, R. He, X. Li Additive inhibition of H1N1 and H3N2 influenza viruses by aurintricarboxylic acid with amantadine. In Options for the Control of Influenza Virus. Page 478-479. J. Katz (Eds). 2008, ISBN: 978-901-769-15-6. International Medical Press. London. U.K.
• He, R, and X. Li.  2008. Mammalian Two-Hybrid Assay for Detecting Protein-Protein Interactions in vivo. Methods Mol Biol. 2008; 439:327-37.
• Huang D, Pereboev AV, Korokhov N, He R, Larocque L, Gravel C, Jaentschke B, Tocchi M, Casley WL, Lemieux M, Curiel DT, Chen W, Li. X. 2007. Significant alterations of biodistribution and immune responses in Balb/c mice administered with adenovirus targeted to CD40(+) cells. Gene Ther. 15:298-308.
• Casley WL, Ogrodowczyk C, Larocque L, Jaentschke B, LeBlanc-Westwood C, Menzies JA, Whitehouse L, Hefford MA, Aubin RA, Thorn CF, Whitehead AS, Li. X. 2007. Cytotoxic doses of ketoconazole affect expression of a subset of hepatic genes. J Toxicol Environ Health A. 70(22):1946-55.
• R. He, A. Adonov, M. Traykova-Adonova, J. Cao, T. Cutts, E. Grudesky, Y. Deschambaul , J Berry, M. Drebot, and X. Li. 2004. Potent Selective Inhibition of SARS Coronavirus Replication by Aurintricarboxylic Acid. Biochem Biophys Res Commun 320:1199-1203.
• He R, A Leeson, F Dobie, M Ballantine, L Baker, A Andonov , Y Li, N Bastien, T Cutts, J Cao, TF Booth, FA Plummer, S Tyler and X. Li. 2004. Characterization of Protein-Protein Interactions between the Nucleocapsid Protein and Membrane Protein of the SARS Coronavirus. Virus Res. 105:121-125.
• R He, F Dobie1, A Leeson1, T Cutts, Y Li, N Bastien, A Andonov, X. Li . 2004. Multimerization of the SARS coronavirus nucleocapsid protein. Biochem Biophys Res Commun. 2004 Apr 2; 316(2):47683.
• He R, A Leeson, Y Li, N Bastien, J Cao, C Osiowy, F Dobie, T Cutts, X. Li . 2003. Activation of AP-1 Signal Transduction pathway by SARS Coronavirus Nucleocapsi Protein. Biochem Biophys Res Commun. 311: 870-876.
• Li, X.,. Josef, W.A. Marasco. 2001.HIV-1 Tat can substantially enhance the capacity of NIK to induce IkB degradation. Biochem Biophys Res Commun. 2001, 286(3):587-94.
• Li, X . , P. Stuckert, J. Josef, W.A. Marasco. 2001. Single-Chain Antibody Mediated-Gene delivery into ErbB2 Positive Human Breast Cancer Cells. Cancer Gene Ther. 2001 Aug 8; (8):555-65.
• Li, X., M.C. Multon, F Schweighoffer, C Venot, J LeVecchio, J. Josef, A. Mhashilkar et al. 2000. Grb3-3 is upregulated by HIV-1 and can potentiate T cell activation through NFATc. J Biol Chem. 2000 Oct 6; 275(40):30925-33.
• Li, X., M.C. Multon, F Schweighoffer, C Venot, J LeVecchio, J. Josef, A. Mhashilkar, et al. 2000. Upregulation of the apoptosis-associated protein Grb3-3 in human immunodeficiency virus type I –infected human CD4(+) lymphocytes. Biochem Biophys Res Commun. 2000 Sep16; 276(1):362-70.
• Li, X., and M. A. Wainberg. 1999. Virology of human immunodeficiency virus type I. In: Infectious Diseases, D. Armstrong and J. Cohen (eds), Morby, London, 1ppp, pp 7.1-7.4.
• Gotte M, Li X, Wainberg MA. 1999. Reverse transcription: structure-function relationships among molecules involved in initiation of the reaction. Arch Biochem Biophys 15; 365(2):199-210.
• Mharshilkar, A, J LeVechio, U. Ramstedt, R. Weismahr, C Pumphrey, X. Li, et al. 1998. Inhibition of HIV-1 replication by humanized single chain antibodies against human immunodeficiency virus type I Tat. Hum Gene Therapy. 1999 Jun 10; 10(9):1453-67.
• Liang, L Rong, M Gotte, X. Li, Y Quan, L Kleiman, M. Wainberg. 1998. Mechanistic studies of early pausing events during initiation of human immunodeficiency virus type I reverse transcription. J Biol Chem. 1998 Aug 14; 273(33):21309-15.
• Cherry, E., X. Li, and M.A. Wainberg: 1998. Inhibition of human immunodeficiency virus type I replication by using transdominant protease mutants. J Mol Biol. Nov 20; 284(1):43-56.
• Morin, N., X. Li, and M.A. Wainberg: 1998. Characterization of transdominant negative human immunodeficiency virus type I Gag-pol mutant proteins on viral particle production and infectivity. J Hum Virol. Mar-Apr; 1(3):240-7.
• Huang, Y., A Korchid, J Gabor, J. Wang, X. Li, et al. 1998. The role of nucleocapside and U5 stem/A-rich loop sequences in tRNALys.3 genomic placement and initiation of reverse transcription in Human Immunodeficiency Virus type 1. J Virol. 1998 May; 72(5):3907-15.
• Quan Y, Z. Gu, X. Li, C. Liang, M. A. Parniak, M. A. Wainberg.1998. Endogenous Reverse Transcriptase Assays Reveal Synergy between Combinations of the M184V and other Drug Resistance-conferring Mutations in Interactions with Nucleoside Analog Triphosphates. J. Mol. Biol. 277: 237-247.
• Li, X., Y. Quan, and M. A. Wainberg. 1997. Controlling Elements in human immunodeficiency virus type I Replication. Cell. Mol. Biol. 43:443-454.
• Liang, C., X. Li, Y. Quan, M. Laughrea, L. Kleiman, J. Hiscott, and M.A. Wainberg. 1997 Sequence elements downstream of the human immunodeficiency virus type 1 long terminal repeats are required for efficient viral gene expression. J. Mol. Biol. 272:167-177.
• Liang, C, X. Li, L. Rong, P. Inuye, Y. Quan, L. Kleiman, and M. A. Wainberg. 1997. The importance of the A-rich loop in human immunodeficiency virus type 1 reverse transcription and infectivity. J. Virol. 71:5750-5757.
• Li, X., C. Liang, Y. Quan, M. Parniak, L. Kleiman, and M.A. Wainberg. 1997 Identification of Sequences downstream of the primer binding site that are critical for efficient replication of the human immunodeficiency virus type 1. J. Virol. 71:6003-6010.
• Arion D., R. Harada, X. Li, M.A. Wainberg, M.A. Parniak. 1996. Human immunodeficiency virus type I reverse transcriptase shows no specificity for the binding of primer tRNALys.3. Biochem. Biophys. Research. Com. 225(3):839-43.
• Arts, E.J., S. Stretor, X. Li, J. W. Rausch, K. J. Howard, B. Ehresmann, T. North, R. G. Goody, M. A. Wainberg, and S. F. J. Le Grice. 1996. Initiation of (-) strand DNA synthesis on lentiviral RNAs: Implication of specific HIV-1 RNA-tRNALys.3 interactions inhibiting primer utilization by retroviral reverse transcriptase. Proc. Natl. Acad. Sci. U.S.A. 93: 10063-8.
• Quan,Y., Z. Gu, X. Li, C.D. Morrow, and M. A. Wainberg. 1996. Endogenous reverse transcription assays reveal high level resistance to the 3TC by mutated M184V human immunodeficiency virus type I. J. Virol. 70:5642-5645.
• Li, X., Y. Quan, E.J. Arts, Z. Li, M. A. Parniak, M.A. Wainberg. 1996. The human immunodeficiency virus type I nucleocapsid protein (NCp7) directs specific initiation of minus strand DNA synthesis primed by tRNALys.3. J. Virol. 70:4996-5004.
• Gu. Z., X. Li., Y. Quan, M.A. Parniak, and M.A. Wainberg. 1996. Studies of a neutralizing monoclonal antibody to human immunodeficiency virus type I reverse transcriptase: antagonistic and synergistic effects in reactions performed in the presence of nucleoside & non-nucleoside inhibitors, respectively. J. Virol. 70:4996-5004.
• Li, X ., J. Mak, E. Arts, Z. Gu, L. Kleiman, M.A. Wainberg, M.A. Parniak. 1994. Effects of alterations of primer binding site sequences on human immunodeficiency virus type 1 replication. J. Virol. 68:6198-6206.
• Arts, E.J., X. Li, Z. Gu, M.A. Parniak, and M.A. Wainberg. 1994. Comparison of deoxy-oligonucleotide and tRNAlys3 as primers in an endogenous human immunodeficiency virus type I in vitro reverse transcription/template switching reaction. J. Biol. Chem. 269: 14672-14680.
• Wu, J., Y. Wang, X. Li, Y. Sheng. 1993. Conformation Changes of p53 proteins in regulation of murine T lymphocyte proliferation. Cell. Mol. Biol. Res. 39:27-31.
• Wu, J., E. Amandoron, X. Li, M.A. Wainberg, M.A. Parniak. 1993. Monoclonal antibody-mediated inhibition of human immunodeficiency virus type I reverse transcriptase polymerase activity. Interaction with a possible deoxynucleoside triphosphate binding domain. J. Biol. Chem. 268: 9980-9985.
• Li, X., Z. Gu, R. Geleziunas, L. Kleiman, M.A. Wainberg, M.A. Parniak. 1993. Expression, purification and RNA-binding properties of human immunodeficiency virus type I p15gag nucleocapsid protein. Protein Expression and Purification. 4:304.
• Li, X. , E. Amandoron, M.A. Wainberg, M.A. Parniak. 1993. Generation and characterization of unique murine monoclonal antibodies reactive against N-terminal and other regions of human immunodeficiecy virus type I reverse transcriptase. J. Med. Virol. 39:251.
• Gu, Z., Q. Gao, X. Li, M.A. Parniak, M.A. Wainberg. 1992. Novel mutation in the human immunodeficiency virus type I reverse transcriptase gene that encodes cross-resistance to ddI and ddC. J. Virol. 66:7128.
• Gao, Q., Z. Gu, M.A. Parniak, X. Li, M.A. Wainberg. 1992. In vitro selection of nucleoside-resistant variants of human immunodeficiency virus type I. J. Virol. 66: 12.
• Wainberg, M.A., M. Tremblay, R. Rooke, N. Blain, H. Soudeyns, M.A. Parniak, X.J. Yao, X. Li et al. 1991. Characterization of reverse transcriptase activity and susceptibility to other nucleosides of AZT-resistant variants of human immunodeficiency virus type I. Ann. N. Y. Acad. Sci. 616:346.
• Rooke. R, M. Parniak, M. Tramblay, H. Soudyns, X. Li.et al. 1991. Biological comparison of wild type and zidovudine-resistant isolates of human immunodeficiency virus type I from some subjects. Antimicrobile Agents and Chemotherapy. 35:988.
• Boulerice, F., X. Li, A. Lvovich, M. Wainberg. 1991. Recovery of infectious human immunodeficiency virus type I after fusion of defectively infected,clones of U-937 cells. J. Virol. 65:5589.
• Tremblay, M., K. Numazaki, X. Li, M. Gornisky, J. Hiscott, M.A. Wainberg. 1990. Resistance to infection by HIV-1 of peripheral blood mononuclear cells from human immunodeficiency virus type I - infected patient is probably mediated by neutralizing antibodies. J. Immunol. 145:2896.
  
  

© University of Ottawa

For additional information, consult our list of contacts

Technical questions? medtech@uottawa.ca